TELA Bio logo

TELA BioNASDAQ: TELA

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 November 2019

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$114.23 M
-58%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-18.21
-120%vs. 3y high
2%vs. sector
-76%vs. 3y high
34%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$2.90-$0.01(-0.34%)

Dividend

No data over the past 3 years
$18.96 M$23.17 M
$18.96 M-$10.37 M

Analysts recommendations

Institutional Ownership

TELA Latest News

TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
globenewswire.com19 November 2024 Sentiment: POSITIVE

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference.

TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
zacks.com07 November 2024 Sentiment: NEGATIVE

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com01 November 2024 Sentiment: POSITIVE

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

TELA Bio to Announce Third Quarter 2024 Financial Results
globenewswire.com17 October 2024 Sentiment: POSITIVE

MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
zacks.com12 August 2024 Sentiment: NEGATIVE

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago.

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
globenewswire.com12 August 2024 Sentiment: POSITIVE

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com09 August 2024 Sentiment: POSITIVE

MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

TELA Bio to Announce Second Quarter 2024 Financial Results
globenewswire.com22 July 2024 Sentiment: POSITIVE

MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

TELA Bio Appoints Jeffrey Blizard to its Board of Directors
globenewswire.com04 June 2024 Sentiment: POSITIVE

MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.

  • 1(current)

What type of business is TELA Bio?

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

What sector is TELA Bio in?

TELA Bio is in the Healthcare sector

What industry is TELA Bio in?

TELA Bio is in the Medical Devices industry

What country is TELA Bio from?

TELA Bio is headquartered in United States

When did TELA Bio go public?

TELA Bio initial public offering (IPO) was on 08 November 2019

What is TELA Bio website?

https://www.telabio.com

Is TELA Bio in the S&P 500?

No, TELA Bio is not included in the S&P 500 index

Is TELA Bio in the NASDAQ 100?

No, TELA Bio is not included in the NASDAQ 100 index

Is TELA Bio in the Dow Jones?

No, TELA Bio is not included in the Dow Jones index

When was TELA Bio the previous earnings report?

No data

When does TELA Bio earnings report?

The next expected earnings date for TELA Bio is 21 March 2025